4596.TSE · Kubota Pharmaceutical Holdings Co., Ltd

-

Please sign in to comment on 4596.TSE

1 Comment

Admin

4 years ago

Kubota Pharmaceutical Holdings Co., Ltd is currently in a long term downtrend where the price is trading 9.3% below its 200 day moving average.

From a valuation standpoint, the stock is 351.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 318.6.

Kubota Pharmaceutical Holdings Co., Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 30.0% to $-566M since the same quarter in the previous year.

Finally, its free cash flow grew by 30.1% to $-511M since the same quarter in the previous year.

Based on the above factors, Kubota Pharmaceutical Holdings Co., Ltd gets an overall score of 2/5.

Exchange	TSE
CurrencyCode	JPY
Sector	Healthcare
Industry	Biotechnology
ISIN	JP3266500002

PE Ratio	None
Dividend Yield	None
Market Cap	3B
Beta	0.89

ABOUT

Kubota Pharmaceutical Holdings Co., Ltd

Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.

4596.TSE · Kubota Pharmaceutical Holdings Co., Ltd

-

Kubota Pharmaceutical Holdings Co., Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Kubota Pharmaceutical Holdings Co., Ltd using a moving average strategy